Efficacy of Chlorella Vulgaris in Elderly Depressed Patients

Phase 3

Recruiting

• Conditions: Major depression.; Major depressive disorder, recurrent, unspecified; F33.9

• Registration Number: IRCT20161010030255N5
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 27 June 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Patients within the age range of 60-80 years
Reading and writing ability
Iranian nationality and ability to speak Persian
Living with at least one family member
Written consent from patient or family member
Diagnosis of major depression based on DSM-V criteria certified by the research director (psychiatrist) that the patient has not been treated for depression at least in the past 4 weeks

Exclusion Criteria

Any serious cognitive disorder
Developing any unpredictable and undesired physical or mental problem during treatment
Consuming Warfarin and chemotherapeutic agents such as; Azathioprine, Basiliximab, Cyclosporine, Daclizumab, Muromonab- CD3, Mycophenolate, Tacrolimus
History of drug and alcohol abuse
Uncontrolled diabetes or thyroid problem

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severity of depression based on Geriatric Depression Scale (GDS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Geriatric Depression Scale (GDS).;Severity of depression based on Depression, Anxiety, Stress Scales (DASS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Depression, Anxiety, Stress Scales (DASS).;Severity of anxiety based on Depression, Anxiety, Stress Scales (DASS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Depression, Anxiety, Stress Scales (DASS).;Severity of stress based on Depression, Anxiety, Stress Scales (DASS). Timepoint: Baseline data, after 6 and 12 weeks. Method of measurement: Persian version of Depression, Anxiety, Stress Scales (DASS).